A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking

Oleson, Erik B.; Cheer, Joseph F.

doi:10.1101/cshperspect.a012229

Cited by 122 publications

(97 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These regions are part of the striatum which has been 414 reported to be connected with both cortical and midbrain 415 dopamine cell body regions [93]. Moreover, cannabis and cocaine 416 affect the mesolimbic dopamine system, including putamen and 417 caudate [94][95][96][97], which is crucial to the reward-processing and 418 drug addiction [98,99]. Indeed, previous studies underlined that a 419 dysfunction in the reward system relate to increased risk of 420 substance abuse [100][101][102].…”

mentioning

confidence: 99%

Structural and metabolic differentiation between bipolar disorder with psychosis and substance-induced psychosis: An integrated MRI/PET study

et al. 2016

View full text Add to dashboard Cite

Keywords:Bipolar disorder Substance-induced psychosis Magnetic resonance imaging (MRI) Positron emission tomography (PET) Gray matter Cerebral metabolism A B S T R A C TBackground: Bipolar disorder (BD) may be characterized by the presence of psychotic symptoms and comorbid substance abuse. In this context, structural and metabolic dysfunctions have been reported in both BD with psychosis and addiction, separately. In this study, we aimed at identifying neural substrates differentiating psychotic BD, with or without substance abuse, versus substance-induced psychosis (SIP) by coupling, for the first time, magnetic resonance imaging (MRI) and positron emission tomography (PET). Methods: Twenty-seven BD type I psychotic patients with (n = 10) or without (n = 17) substance abuse, 16 SIP patients and 54 healthy controls were enrolled in this study. 3T MRI and 18-FDG-PET scanning were acquired. Results: Gray matter (GM) volume and cerebral metabolism reductions in temporal cortices were observed in all patients compared to healthy controls. Moreover, a distinct pattern of fronto-limbic alterations were found in patients with substance abuse. Specifically, BD patients with substance abuse showed volume reductions in ventrolateral prefrontal cortex, anterior cingulate, insula and thalamus, whereas SIP patients in dorsolateral prefrontal cortex and posterior cingulate. Common alterations in cerebellum and parahippocampus were found in both BD with substance abuse and SIP. Finally, a unique pattern of GM volumes reduction, with concomitant increased of striatal metabolism, were observed in SIP patients. Conclusions: These findings contribute to shed light on the identification of common and distinct neural markers associated with bipolar psychosis and substance abuse. Future longitudinal studies should explore the effect of single substances of abuse in patients at the first-episode of BD and substanceinduced psychosis.ß 2016 Elsevier Masson SAS. All rights reserved.

show abstract

mentioning

confidence: 99%

Structural and metabolic differentiation between bipolar disorder with psychosis and substance-induced psychosis: An integrated MRI/PET study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Por ejemplo, el cannabidiol, uno de los componentes de la marihuana, ha resultado ser bien tolerado y efectivo en el tratamiento de los síntomas psicóticos (Iseger & Bossong, 2015). Por otro lado, la interacción entre el sistema endocannabinoide y el sistema dopaminérgico puede influenciar fenómenos que incluyen la abstinencia y la expectativa de recompensa condicionada por la sustancia adictiva (Oleson & Cheer, 2012). Esta relación también sugieren que el aumento de la dopamina estriatal se relaciona con los efectos agudos del cannabis (Ghazzaoui & Abi-Dargham, 2014).…”

Section: Sistema Endocannabinoideunclassified

Neurobiología de la Patología Dual

Bernal¹,

Pérez²

2017

HAAJ

View full text Add to dashboard Cite

show abstract

“…The stimulation of dopamine mesolimbic neurotransmission is essential for the reinforcing effects of many drugs of abuse, including cannabinoids (39,40). In the VTA, CB 1 cannabinoid receptors are located on presynaptic glutamatergic and GABAergic neurons where they modulate the excitatory and inhibitory inputs on mesolimbic dopaminergic neurons (41).…”

Section: The Enhanced Of Dopamine Extracellular Levels In the Nucleusmentioning

confidence: 99%

The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward

Flores

Maldonado

Berrendero

2014

Biological Psychiatry

View full text Add to dashboard Cite

Table 1) 2 Background: Cannabis is the most widely used illicit drug in the world. Although there is a high prevalence of users who seek treatment for cannabis dependence, no accepted pharmacological treatment is still available to facilitate and maintain abstinence. The hypocretin/orexin system plays a critical role in drug addiction and the potential participation of this system in the addictive properties of cannabinoids is still unknown. Methods:We investigated the effects of hypocretins in the intravenous selfadministration of the synthetic cannabinoid agonist WIN55,212-2 using hypocretin receptor-1 (Hcrtr-1) and hypocretin receptor-2 (Hcrtr-2) antagonists, and Hcrtr-1 knockout mice. Additional groups of mice were trained to obtain water to rule out operant responding impairments. Activation of hypocretin neurons was analyzed by using double label immunofluorescence of FosB/∆FosB with hypocretin-1.Microdialysis studies were performed to evaluate dopamine extracellular levels in the nucleus accumbens after acute ∆ 9 -tetrahydrocannabinol (THC) administration.Results: Systemic administration of the Hcrtr-1 antagonist SB334867, but not the Hctr-2 antagonist TCSOX229, reduced intravenous self-administration of WIN55,212-2 as well as the maximum effort to obtain a WIN55,212-2 infusion as revealed under a progressive ratio schedule. This role of Hcrtr-1 in the reinforcing and motivational properties of WIN55,212-2 was confirmed in Hcrtr-1 knockout mice. Contingent, but not non-contingent WIN55,212-2 self-administration increased the percentage of hypocretin cells expressing FosB/∆FosB in the lateral hypothalamus. The enhancement in dopamine extracellular levels in the nucleus accumbens induced by THC was blocked in mice lacking the Hcrtr-1.Conclusions: These findings demonstrate that Hcrtr-1 modulates the reinforcing properties of cannabinoids, which could have a clear therapeutic interest. 3 IntroductionCannabis is the most used illicit drug worldwide (1). It is estimated that about 9% of those who ever use this drug become daily users (2), rising to 16% when the consumption is initiated during the adolescence (2). Recent analysis of cannabis extracts has shown an increase in potency over the last years due to enhanced content of ∆ 9 -tetrahydrocannabinol (THC), its primary psychoactive constituent (3). A high THC content leads to an increase in the subjective effects of this drug probably enhancing the risk of dependence and psychotic symptoms of cannabis users (3). Treatment admissions for cannabis-use disorders have progressively increased in the past decade.Approximately 90% of those seeking treatment for these disorders have great difficulty achieving and sustaining periods of abstinence (4), and the majority relapse to use following therapeutic interventions (5). There are currently no effective pharmacotherapeutic approaches for this disorder (5). Therefore, the need for identifying specific medications to improve treatment outcomes for cannabis dependence becomes a major clinical priority.Several findin...

show abstract

A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking

Cited by 122 publications

References 80 publications

Structural and metabolic differentiation between bipolar disorder with psychosis and substance-induced psychosis: An integrated MRI/PET study

Structural and metabolic differentiation between bipolar disorder with psychosis and substance-induced psychosis: An integrated MRI/PET study

Neurobiología de la Patología Dual

The Hypocretin/Orexin Receptor-1 as a Novel Target to Modulate Cannabinoid Reward

Contact Info

Product

Resources

About